Saturday 17 October 2026
Export AKBA’s income statement to Excel — free account
Akebia Therapeutics, Inc.
AKBA Healthcare Drug Manufacturers Specialty & Generic
Akebia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $236.2 million, up 47.5% from fiscal 2024. In the quarter to June 2026, revenue fell 21.4%, EPS fell 3,433.3%, free cash flow fell 89.0% and total debt rose 5.31%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.67
0.03
−4.29%
Follow AKBA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
7 | 3 | 3 | 6 | 2 | 3 | 2 | 3 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(4.42) | (9.61) | (8.54) | (5.68) | (4.60) | (3.11) | (0.88) | (0.33) | 0.70 | (1.14) |
P/S ratio |
1.75 | 2.50 | 1.22 | 0.39 | 1.77 | 1.32 | 2.23 | 1.54 | 3.59 | 0.00 |
P/FCF ratio |
6.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.17 |
Altman Z″-Score (non-manufacturers) |
(12.49) | (25.54) | (22.61) | (14.74) | (12.07) | (7.37) | (3.89) | 0.30 | (0.29) | (1.99) |
Beneish M-Score |
(3.16) | (3.29) | (2.84) | (2.97) | (2.93) | (3.69) | (2.71) | 35.30 | 101.14 | — |
P/Operating CF |
13.30 | (89.74) | (103.15) | (2.07) | (5.97) | (12.59) | (8.12) | (4.35) | (39.76) | 4.14 |
P/B ratio |
12.70 | 0.00 | 0.00 | 21.67 | 5.07 | 1.57 | 1.90 | 0.50 | 5.31 | 5.81 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.01 | 15.43 | 1.27 | 5.31 | 5.81 |
EV/Sales |
1.25 | 2.53 | 1.18 | 0.30 | 1.94 | 0.88 | 2.03 | 1.11 | 1.84 | 0.00 |
EV/EBITDA |
11.91 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
4.34 | (9.96) | (9.83) | (1.22) | (1.62) | (2.36) | (2.65) | (2.37) | (5.94) | 2.34 |
EV/FCF |
4.35 | (9.96) | (9.78) | (1.21) | (1.62) | (2.30) | (2.58) | (2.33) | (5.77) | 2.46 |
Quick Ratio |
1.42 | 1.07 | 0.82 | 1.01 | 0.77 | 1.58 | 0.90 | 1.27 | 2.49 | 2.57 |
Current Ratio |
1.55 | 1.41 | 1.18 | 1.43 | 1.04 | 1.98 | 1.49 | 1.76 | 2.54 | 2.59 |
Net Debt/EBITDA |
(5.51) | 1.02 | 0.96 | 0.57 | (0.15) | 0.56 | 0.27 | 0.51 | 4.21 | 1.92 |
Debt/Assets |
12.81% | 17.53% | 14.35% | 18.56% | 34.86% | 15.74% | 10.48% | 1.51% | 0.00% | 0.00% |
Debt/Equity |
1.48 | (0.79) | (1.13) | 12.63 | 2.49 | 0.41 | 0.20 | 0.02 | 0.00 | 0.00 |
Asset Turnover |
0.79 | 0.69 | 0.65 | 0.66 | 0.36 | 0.42 | 0.38 | 0.31 | 0.55 | 0.01 |
Operating CF/Net income |
(12.72) | 0.59 | 0.45 | 0.78 | 0.90 | 0.29 | 0.92 | 0.68 | 0.76 | (0.43) |
Capex/Depreciation |
(0.09) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.18) | (1.35) | (1.32) | (3.37) |
Interest Coverage |
0.97 | (2.78) | (7.67) | (5.15) | (13.27) | (42.59) | 361.47 | (28.95) | (27.39) | (151.45) |
| 64.49% | 174.03% | 409.60% | (237.83%) | (175.37%) | (119.82%) | (54.27%) | (37.86%) | (77.27%) | (136.35%) | |
| (1.79%) | (30.02%) | (17.37%) | (21.28%) | (48.07%) | (54.38%) | (31.64%) | (21.10%) | (22.17%) | (61.26%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (152.01%) | (196.30%) | (54.53%) | (20.38%) | 0.00% | 0.00% |
Return on Tangible Assets |
(5.86%) | (197.65%) | (237.01%) | (154.82%) | (1,673.53%) | (199.49%) | (250.15%) | (68.18%) | (33.36%) | (73.51%) |
Average Days of Receivables |
72.68 | 78.31 | 73.69 | 50.27 | 88.95 | 82.81 | 42.61 | 410.54 | 68.91 | 8,042.60 |
Research and Development Expense of Revenue |
26.40% | 23.51% | 32.41% | 44.44% | 69.86% | 74.15% | 96.41% | 140.08% | 127.41% | 7,543.00% |
Selling, General and Administrative Expense of Revenue |
45.50% | 66.52% | 51.50% | 47.39% | 82.28% | 52.30% | 44.61% | 41.91% | 14.90% | 1,446.91% |
Intangible Assets out of Total Assets |
0.16 | 0.27 | 0.39 | 0.37 | 0.32 | 0.31 | 0.45 | 0.38 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
4.78% | 4.85% | 4.79% | 6.10% | 10.74% | 8.30% | 3.56% | 9.17% | 4.89% | 379.48% |
Graham Net Nets |
(0.22) | (0.39) | (0.65) | (1.46) | (0.49) | (0.06) | (0.09) | 0.34 | 0.18 | 0.16 |
Graham Number |
0.00 | 1.32 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(1.06%) | (17.37%) | (22.05%) | (82.26%) | (75.22%) | (98.93%) | (37.34%) | (44.67%) | (12.76%) | (34.29%) |
Free Cash Flow Yield |
16.39% | (10.15%) | (9.87%) | (64.65%) | (67.46%) | (29.28%) | (35.29%) | (30.88%) | (8.87%) | 13.95% |
Revenue per Share |
0.92 | 0.76 | 1.04 | 1.60 | 1.28 | 2.13 | 2.83 | 3.58 | 4.17 | 0.04 |
Operating CF per Share |
0.26 | (0.19) | (0.12) | (0.40) | (1.52) | (0.80) | (2.17) | (1.68) | (1.29) | 1.54 |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.06) | (0.03) | (0.04) | (0.07) |
Free Cash Flow per Share |
0.26 | (0.19) | (0.12) | (0.40) | (1.52) | (0.80) | (2.23) | (1.71) | (1.33) | 1.46 |
Cash per Share |
0.72 | 0.25 | 0.23 | 0.49 | 0.90 | 1.65 | 1.25 | 1.80 | 7.31 | 6.90 |
Shareholders Equity per Share |
0.13 | (0.23) | (0.16) | 0.03 | 0.45 | 1.79 | 3.33 | 10.96 | 2.82 | 1.81 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.13 | (0.23) | (0.16) | 0.03 | 0.45 | 1.79 | 3.33 | 10.96 | 2.82 | 1.81 |
Free Cash Flow |
67.87 | (40.69) | (23.38) | (73.27) | (253.02) | (110.70) | (264.10) | (99.10) | (57.78) | 55.24 |
Working Capital |
90.02 | 32.92 | 18.28 | 55.65 | 10.10 | 184.29 | 101.42 | 202.58 | 217.25 | 182.05 |
Capital Expenditures |
(0.12) | (0.03) | — | (0.11) | (0.06) | (0.32) | (6.65) | (1.61) | (1.62) | (2.66) |
Net Current Asset Value |
(91.00) | (156.02) | (154.14) | (165.64) | (184.19) | (25.08) | (66.91) | 107.66 | 116.68 | 64.23 |
EV/EBIT |
12.55 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 1.73 |
Price to Operating Income |
17.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.04 | 17.05 | 10.37 | 7.23 | 5.62 | 17.29 | 3.64 | 0.15 | 0.34 | 0.30 |
Cash ROIC |
25.54% | (98.34%) | (49.73%) | (45.29%) | (61.96%) | (19.16%) | (42.39%) | (13.12%) | (13.12%) | 16.82% |
Accounts Receivable Turnover |
5.80 | 4.35 | 4.89 | 6.37 | 3.57 | 5.56 | 2.46 | 1.55 | 5.33 | 0.09 |
Accounts Payable Turnover |
2.17 | 4.24 | 4.54 | 3.32 | 4.02 | 4.52 | 3.54 | 0.31 | 0.14 | 0.00 |
Inventory Turnover |
2.48 | 3.96 | 3.98 | 2.94 | 3.09 | 2.05 | 1.26 | 0.07 | 0.00 | — |
Average Days of Payables |
195.95 | 87.70 | 72.04 | 76.87 | 81.37 | 82.82 | 98.49 | 2,010.88 | 4,139.82 | 0.00 |
Days of Inventory on Hand |
144.38 | 93.84 | 77.24 | 92.00 | 88.73 | 122.33 | 292.20 | 5,368.10 | 0.00 | — |
Average Receivables |
40.70 | 36.83 | 39.79 | 45.93 | 59.21 | 52.98 | 136.39 | 133.94 | 34.02 | 16.98 |
Average Payables |
18.18 | 14.91 | 16.33 | 25.80 | 37.45 | 40.26 | 41.01 | 24.90 | 4.52 | 2.18 |
Average Inventory |
15.93 | 15.97 | 18.63 | 29.10 | 48.82 | 88.68 | 115.30 | 115.00 | — | — |
Average Assets |
298.62 | 231.19 | 298.88 | 442.70 | 586.74 | 707.67 | 883.87 | 680.39 | 332.23 | 221.58 |
Average Common Equity |
(8.29) | (39.88) | (12.68) | 39.62 | 160.81 | 321.19 | 515.34 | 379.25 | 95.35 | 99.56 |
Columns are period end dates